ストックスクリーナーアプリを入手
3.54
6.10%
-0.23
プレマーケット:
3.55
0.010
+0.28%
Aardvark Therapeutics Inc (AARD) 最新ニュース
Decliners Report: Can Aardvark Therapeutics Inc outperform under higher oil prices2026 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Stockholders to Connect - ACCESS Newswire
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Jones Trading cuts Aardvark Therapeutics stock price target on trial delay - Investing.com Australia
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com - Investing.com UK
Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information - Minichart
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating By Investing.com - Investing.com Canada
B.Riley cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com South Africa
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Aardvark Therapeutics Inc. has officially signed an equity distribution agreement with Piper Sandler. - Bitget
Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks - TipRanks
B.Riley cuts Aardvark Therapeutics stock price target on trial pause - Investing.com India
Aardvark Therapeutics Pauses Phase 3 Trials for ARD-101 in Prader-Willi Syndrome, Reports 2025 Financial Results and Pipeline Updates - Minichart
Aardvark Therapeutics Establishes $150 Million Equity Program - TipRanks
Aardvark Therapeutics (NASDAQ: AARD) launches $150M at-the-market stock program - Stock Titan
Aardvark Therapeutics Launches $150 Million ATM Equity Program With Piper Sandler - TradingView
Aardvark Therapeutics, Inc. – Clinical-Stage Biopharma Advancing TAS2R Small-Molecule Therapies for Obesity and Metabolic Diseases - Minichart
Aardvark Therapeutics Files $400 Million Mixed Shelf - marketscreener.com
Aardvark Therapeutics (AARD) registers $400M shelf; $150M ATM included - Stock Titan
Aardvark Therapeutics reports fourth quarter and full year 2025 financial results and provides business updates - marketscreener.com
Aardvark Therapeutics 10-K: $0 Revenue; $(2.93) EPS - TradingView
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Aardvark Therapeutics (AARD) halts ARD-101 PWS Phase 3 to probe cardiac signal - Stock Titan
AARD: Clinical trial pauses and strong cash reserves define the period, with guidance due in Q2 2026 - TradingView
Aardvark Therapeutics (NASDAQ: AARD) halts ARD-101 and ARD-201 trials as 2025 loss widens - Stock Titan
Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) EstimateAardvark Therapeutics (NASDAQ:AARD) - Benzinga
Aardvark halts obesity and PWS studies after reversible heart findings - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Breakouts Watch: Can Aardvark Therapeutics Inc expand its profit margins2026 Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Investors to Inquire about Securities Investigation - ACCESS Newswire
If You Invested $1,000 in Aardvark Therapeutics (AARD) - Stock Titan
AARD SEC FilingsAardvark Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aardvark’s ARD-101 Prader-Willi Study Suspended: What Investors Should Watch Next - TipRanks
Aardvark’s HERO Extension Trial Paused: What ARD-101’s Status Means for Investors - TipRanks
Aardvark Therapeutics, Inc. (AARD) - MSN
HC Wainwright & Co. downgrades Aardvark Therapeutics (AARD) - MSN
Earnings Recap: Can Aardvark Therapeutics Inc reach all time highs this year - baoquankhu1.vn
AARD stock slumps 54% pre-market – here’s why analysts are not comfortable with the suspension of a key phase 3 trial - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent
Arcellx and Aardvark Therapeutics Compared - National Today
Analyzing Arcellx (NASDAQ:ACLX) and Aardvark Therapeutics (NASDAQ:AARD) - Defense World
Aug Wrap: Does Aardvark Therapeutics Inc have a competitive edge2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Cresset Asset Management Invests $1.95M in Aardvark Therapeutics - National Today
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
New Highs: Should I trade or invest in Aardvark Therapeutics Inc2025 Market Outlook & Low Risk High Win Rate Picks - baoquankhu1.vn
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves - simplywall.st
NOTICE TO DISREGARD -- Pomerantz LLP - GlobeNewswire Inc.
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial - Yahoo Finance
uniQure loses $1B after FDA rejects Huntington’s data, Aardvark falls on cardiac safety signal, and more - BioCentury
What's Going On With Aardvark Therapeutics Stock On Wednesday? - Bitget
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
AARDAardvark Therapeutics Latest Stock News & Market Updates - Stock Titan
Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions - Yahoo Finance
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
1.82%
大文字化:
|
ボリューム (24 時間):